Posaconazole for Toenail Onychomycosis.

NewsBot · Oct 6, 2011

Members do not see these Ads. Sign Up.
A Randomised, Placebo- and Active-Controlled, Parallel-Group, Multicentre, Investigator-Blinded Study of Four Treatment Regimens of Posaconazole in Adults With Toenail Onychomycosis.
Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A.
Br J Dermatol. 2011 Oct 3.

Background: Onychomycosis accounts for up to 50% of all onychopathies. Objectives: To evaluate the efficacy of four posaconazole regimens compared with placebo in the treatment of toenail onychomycosis, to assess the safety and tolerability of posaconazole, and to estimate the relative efficacy of posaconazole against terbinafine.

Patients/Methods: A phase 2B, randomised, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study (ClinicalTrials.gov identifier: NCT00491764). Onychomycosis patients aged 18-75 years (N = 218) were equally randomised to one of six treatment regimens: posaconazole (oral suspension) 100, 200, or 400 mg once daily (QD) (24 weeks); posaconazole 400 mg QD (12 weeks); terbinafine (tablets) 250 mg QD (12 weeks); or placebo (24 weeks). The primary efficacy variable was complete cure (negative mycology and 0% nail involvement) at week 48.

Results: All posaconazole treatment arms had a significantly (P≤0.012) greater proportion of patients with complete cure at week 48 compared with placebo. The proportions of patients with complete cure were numerically higher for posaconazole 200 mg/24 weeks (54.1%) and 400 mg/24 weeks (45.5%) but lower for 200 mg/12 weeks (20.0%) compared with terbinafine (37%) (differences were not statistically significant). Posaconazole was well tolerated. Seven patients receiving posaconazole withdrew because of asymptomatic liver enzyme increases, as mandated by protocol discontinuation criteria.

Conclusion: The efficacy and favourable safety profile of posaconazole suggest a potential new treatment for onychomycosis. The availability of low-cost generic terbinafine may limit posaconazole use to second-line treatment of infections refractory to, or patients intolerant of, terbinafine, or nondermatophyte mould infections.
Click to expand...

NewsBot The Admin that posts the news.

Ultrasound clinical references of the healthy toenail unit

Extreme pain after toenail removal--normal?

Injection therapy for ingrown toenails

Toenail Dust as a Potential Occupational Hazard in Podiatric Medicine

Spiculectomy and Orthonyxia for Ingrown Toenails

Self-Administered Treatment Kit for Ingrowing Toenail

Terminal Syme amputation in kids for ingrown toenail

Share This Page